What was the issue addressed by this study?
Crohn’s disease occurs when the immune system within the intestine starts reacting to the harmless bacteria that live alongside it as if they were a threat. In many ways, it is surprising that we all don’t develop this disease as the immune system lives side-by-side with huge numbers of intestinal bacteria in all of us. To prevent this reaction occurring, the immune system produces chemicals such as IL-10 that reduce these responses.
We do not fully understand why some people develop Crohn’s disease, but past research has shown that certain immune cells become “reprogrammed” to stop responding to IL-10, increasing inflammation and contributing to the symptoms of Crohn’s.
Although all cells have the same genes within them, the genes are switched on (expressed) and off through a process called epigenetics. The research team have found that the genes expressed by monocytes in Crohn’s disease are quite different to those from healthy people, suggesting that this reprogramming has wide-ranging effects on the activity of these cells.
What was the aim of this study?
The research team wanted to understand this epigenetic reprogramming of immune cells called monocytes in Crohn’s disease and in particular how it contributes to an inability to respond properly to IL-10. The team examined samples taken from patients recently diagnosed with Crohn’s disease who had not yet started drug treatment. They found changes in how DNA is expressed in monocytes gathered from patients with Crohn’s, discovering new pathways of how the disease develops and therefore potential new strategies for treatment.
The research team
This project is led by Dr Andrew Stagg at Queen Mary University of London. Watch the video to below to hear from Dr Stagg about why this research is important:
Final Report Summary
In Crohn’s disease (CD), immune cells called macrophages in the wall of the bowel are changed such that they produce chemicals that drive the inflammatory process that is responsible for the disease. These cells are not long-lived and are instead maintained by bringing in monocytes from the blood that then give rise to new macrophages. We have recently discovered that in CD some inflammatory changes occur in monocytes before they get recruited to the gut ( a phenomenon we call ‘systemic programming’). We know this because monocytes in CD express different genes than do similar cells from healthy people. In the current study, we have begun to explore whether this systemic programming involves changes to key CD genes that leave them poised to become more readily expressed later on. These ‘epigenetic’ changes involve modifications that make the genes more accessible to the molecular machinery responsible for switching them on. We wanted to use modern techniques that enable gene expression and chromatin accessibility to be measured at the same time in individual cells. These are technically demanding experiments, and therefore we conducted a small pilot study looking at cells from a limited number of CD patients and healthy controls (three individuals in each group). We studied newly diagnosed patients before they started treatment because the drugs involved in treatment could affect our findings. In this way, we were able to confirm the feasibility of the approach and identified, for the first time, changes in chromatin accessibility in monocytes from CD patients. These changes indicated that the monocyte population we were studying is more complex than we thought. By exploring the relationship between chromatin accessibility and gene expression, we identified a group of disease-relevant genes that are poised for expression in CD and we identified likely pathways that would regulate this expression. These early findings suggest that monocytes in blood, which are more accessible than their descendants in the intestine, could be targets for new IBD treatments. We next wish to confirm and extend these preliminary findings in order to explore this concept further.
Impact of Bowel Research UK funding
Funding from Bowel Research UK was essential; this work would not have been done without it. New techniques such as the multiomic analysis employed here undoubtedly offer exciting new opportunities to better understand conditions such as IBD. However, this type of technically demanding analysis is costly. Therefore, a major study is unlikely to be funded without compelling pilot data demonstrating feasibility and providing preliminary indications that the approach will be informative and fruitful. Funding from Bowel Research UK has made it possible for us to obtain just this sort of critical data.
Related Research
- Immune responses in Crohn’s disease
- The role of specific T cells in inflammatory bowel disease
- Studying the microbiome to target bowel cancer